Dexcom: Thoughts on the recent G7 rollout and future product strategy?

Curious to hear what people think about the G7 rollout. Seemed like a bit of a bumpy start, but are we seeing positive traction now? More importantly, what's the general feeling about the pipeline beyond G7? I know there's always a lot of R&D going on, but sometimes it feels like the focus can shift based on market pressures or competitive moves. Are there any exciting projects or areas that are getting a lot of internal buzz and investment? Conversely, are there any areas that seem to be getting deprioritized or seeing less attention than before? Just trying to understand where the company's strategic focus really lies for the next few years, especially in light of the general medtech landscape. Any insights from those closer to product development or strategy would be greatly appreciated.